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Abstract
Background: Transforming growth factor beta 1 (TGFβ1) is strongly induced following brain injury and polarises
microglia to an anti-inflammatory phenotype. Augmentation of TGFβ1 responses may therefore be beneficial in
preventing inflammation in neurological disorders including stroke and neurodegenerative diseases. However,
several other cell types display immunogenic potential and identifying the effect of TGFβ1 on these cells is required
to more fully understand its effects on brain inflammation. Pericytes are multifunctional cells which ensheath the
brain vasculature and have garnered recent attention with respect to their immunomodulatory potential. Here, we
sought to investigate the inflammatory phenotype adopted by TGFβ1-stimulated human brain pericytes.
Methods: Microarray analysis was performed to examine transcriptome-wide changes in TGFβ1-stimulated
pericytes, and results were validated by qRT-PCR and cytometric bead arrays. Flow cytometry,
immunocytochemistry and LDH/Alamar Blue® viability assays were utilised to examine phagocytic capacity of
human brain pericytes, transcription factor modulation and pericyte health.
Results: TGFβ1 treatment of primary human brain pericytes induced the expression of several inflammatory-related
genes (NOX4, COX2, IL6 and MMP2) and attenuated others (IL8, CX3CL1, MCP1 and VCAM1). A synergistic induction of
IL-6 was seen with IL-1β/TGFβ1 treatment whilst TGFβ1 attenuated the IL-1β-induced expression of CX3CL1, MCP-1
and sVCAM-1. TGFβ1 was found to signal through SMAD2/3 transcription factors but did not modify nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB) translocation. Furthermore, TGFβ1 attenuated the phagocytic
ability of pericytes, possibly through downregulation of the scavenger receptors CD36, CD47 and CD68. Whilst
TGFβ did decrease pericyte number, this was due to a reduction in proliferation, not apoptotic death or
compromised cell viability.
Conclusions: TGFβ1 attenuated pericyte expression of key chemokines and adhesion molecules involved in CNS
leukocyte trafficking and the modulation of microglial function, as well as reduced the phagocytic ability of
pericytes. However, TGFβ1 also enhanced the expression of classical pro-inflammatory cytokines and enzymes
which can disrupt BBB functioning, suggesting that pericytes adopt a phenotype which is neither solely pro- nor
anti-inflammatory. Whilst the effects of pericyte modulation by TGFβ1 in vivo are difficult to infer, the reduction in
pericyte proliferation together with the elevated IL-6, MMP-2 and NOX4 and reduced phagocytosis suggests a
detrimental action of TGFβ1 on neurovasculature.
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Background
Neuroinflammation contributes to the development and
progression of epilepsy [1], traumatic brain injuries [2],
stroke [3] and many neurodegenerative diseases [4]. In-
flammatory cytokines are key mediators of the brain’s
immune response and associated neurodegeneration [5].
Transforming growth factor beta (TGFβ) is a pleiotropic
cytokine in the brain with roles in regulating cell prolifera-
tion, differentiation, survival and scar formation [6–9].
Furthermore, TGFβ orchestrates both pro- and anti-
inflammatory responses in a cell and context-dependent
manner [10–12]. TGFβ exists in three isoforms (TGFβ1–3),
of which TGFB1 was the first identified and is the most
widely studied. TGFβ exerts its actions through the serine/
threonine kinase receptors, transforming growth factor beta
receptor 1 (TGFBR1), TGFBR2 and TGFBR3. Activation of
TGFBRs by TGFβ ligand binding initiates a signal transduc-
tion pathway predominantly through SMAD transcription
factors [13].
Several cell types in the central nervous system (CNS)
are capable of producing TGFβ1. Endothelial cells secrete
this growth factor, and this is enhanced by co-culture with
pericytes [14, 15]. Following brain injury, microglia and as-
trocytes produce large concentrations of TGFβ1 [8, 16, 17],
whilst glioblastoma multiforme enhances TGFβ1 expres-
sion, possibly due to the increased and abnormal angiogen-
esis [18–20]. Furthermore, TGFβ1 is elevated in several
inflammatory conditions including Alzheimer’s disease,
type 1 diabetes mellitus and acute brain injuries such as is-
chaemic stroke [21–24].
A number of immunologically active brain cells express
TGFBRs and can therefore respond to secretions of this
growth factor. Microglia are the brain’s predominant im-
mune cell and the most widely studied with respect to their
inflammatory response [25]. TGFβ1 promotes a strong
anti-inflammatory phenotype in microglia through attenu-
ated cytokine, chemokine, adhesion molecule and reactive
oxidative species (ROS) production; however, it has no ef-
fect on human leukocyte antigen (HLA) antigen presenta-
tion complexes [10, 26–28]. Furthermore, TGFβ1 enhances
microglial phagocytosis of amyloid beta, thereby reducing
plaque burden [29]. Astrocytes show a more complex regu-
lation of immune responses by TGFβ1 stimulation, with re-
ports of both enhancement and inhibition of chemokine
and cytokine production [11, 12, 30, 31]. Other cells, in-
cluding those derived from the choroid plexus and lepto-
meninges, also display attenuated inflammatory responses
with TGFβ1 treatment [27, 32].
Previous work in our lab using human brain pericytes
demonstrated a reduction in interferon gamma (IFNγ)-in-
duced HLA-DR, HLA-DP and HLA-DQ expression with
TGFβ1 treatment, suggesting an anti-inflammatory role
[27]. Pericytes are multifunctional cells that surround endo-
thelial cells and contact numerous parenchymal brain cells
including astrocytes, neurons and microglia to form a neu-
rovascular unit [33]. Pericyte coverage of brain vasculature
is vital with respect to blood-brain barrier (BBB) formation
and maintenance [34–36]. Several labs, including our own,
have shown that pericytes can contribute to the brain’s im-
mune response through cytokine, chemokine and adhesion
molecule expression and that they display phagocytic po-
tential [37–42].
The function of TGFβ1 on pericytes has been briefly
studied, however, largely with respect to differentiation,
proliferation or angiogenesis [43, 44]. Little is known
about the role of TGFβ1 in the context of human brain
pericyte immune function. We therefore sought to in-




Human middle temporal gyrus brain tissue was obtained,
with informed consent, from surgeries of patients with
drug-resistant temporal lobe epilepsy. All specimens were
collected with written patient consent. All protocols used
in this study were approved by the Northern Regional
Ethics Committee (New Zealand), and all methods were
carried out in accordance with the approved guidelines.
Mixed glial cultures isolated from human brain tissue
Mixed glial cultures containing astrocytes, pericytes and
microglia were isolated from adult human brain tissue with
minor modifications as described previously [45]. As per
[42], cells were grown until passage five before use in order
to dilute out non-proliferating microglia and astrocytes and
obtain a pure pericyte population. Pericyte cultures at pas-
sages five-eight were used for all experiments. Detailed
characterisation of pericyte cultures has been performed
previously [37, 42].
Cytokine and drug treatments
To examine the effect of cytokines on pericyte responses,
cells were treated with 0.1–10 ng/mL TGFβ1 (PeproTech,
NJ, USA; vehicle, 1 mM citric acid, pH 3 with 0.1 % bovine
serum albumin (BSA)) or interleukin 1 beta (IL-1β; Pepro-
tech, NJ, USA; vehicle, 0.1 % BSA in phosphate buffered sa-
line (PBS)) for 0–72 h. Details for each experiment are
noted in appropriate figure legends. To induce apoptosis as
a positive control for cleaved caspase 3 (CC3) staining, peri-
cytes were treated with 50 nM okadaic acid (Sigma-Aldrich,
MO, USA) for 24 h. Cells were treated with drugs/cytokines
by addition of a 1:100 dilution of a 100 × stock.
Collection of conditioned media and cytokine
measurement by cytometric bead array
Conditioned media was collected from cells grown in a
96-well plate. Media was spun at 160×g for 5 min to
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collect any detached cells or debris. Supernatant was
obtained and stored at −20 °C. The concentration of cy-
tokines was measured using a cytometric bead array
(CBA; BD Biosciences, CA, USA) as per manufacturer’s
instructions. CBA samples were run on an Accuri C6
flow cytometer (BD Biosciences, CA, USA). Data was
analysed using FCAP-array software (version 3.1; BD
Biosciences, CA, USA) to convert fluorescent intensity
values to concentrations using a ten-point standard
curve (0–5000 pg/mL) as described previously [46].
Immunocytochemistry
Cells were fixed in 4 % paraformaldehyde (PFA) for
15 min and washed in PBS with 0.1 % triton X-100
(PBS-T). Cells were incubated with primary antibodies
(Additional file 1: Table S1) overnight at 4 °C in immu-
nobuffer containing 1 % goat serum, 0.2 % Triton X-100
and 0.04 % thimerosal in PBS. Cells were washed in
PBS-T and incubated with appropriate anti-species fluo-
rescently conjugated secondary antibodies overnight at
4 °C. Cells were washed again and incubated with
Hoechst 33258 (Sigma-Aldrich, MO, USA) for 20 min.
Images were acquired at ×10 magnification using the au-
tomated fluorescence microscope ImageXpress® Micro
XLS (version 5.3.0.1, Molecular Devices, CA, USA).
Quantitative analysis of intensity measures and positively
stained cells was performed using the Cell Scoring and
Show Region Statistics analysis modules on MetaXpress®
software (version 5.3.0.1, Molecular Devices, CA, USA).
Phagocytosis assays
To evaluate phagocytosis by microscopy, cells were treated
with 0–10 ng/mLTGFβ1 for 24 h, followed by a further 24-
h incubation with Fluoresbrite® YG carboxylate micro-
spheres of 1 μm diameter (Polysciences Inc, PA, USA;
1:1000 dilution) at 37 °C, 5 % CO2. At completion, cells
were washed twice with PBS to remove un-phagocytosed
beads and fixed in 4 % PFA as per immunocytochemistry.
Nuclear staining was visualised by a 30-min incubation
with the DNA-specific dye DRAQ5 (BioStatus, UK). Images
were obtained using the ImageXpress® Micro XLS micro-
scope and the percentage of phagocytic cells determined
using the Cell Scoring module on MetaXpress® software.
To evaluate phagocytosis by flow cytometry, cells were
treated with 0–10 ng/mL TGFβ1 for 24 h, followed by a
further 2-h incubation with Fluoresbrite® YG carboxylate
microspheres of 1-μm diameter (1:1000 dilution) at 37 °C,
5 % CO2. At completion, cells were washed twice with
PBS, and 0.25 % trypsin-ethylenediaminetetraacetic acid
(EDTA) was added to remove beads bound to the cell sur-
face and bring cells into suspension. Selected samples
were incubated for 10 min with 7-aminoactinomycin D
(7-AAD; BD Biosciences, CA, USA) to assess viability.
Samples were run on an Accuri C6 flow cytometer and
viable cells gated based on forward scatter and side scat-
ter. Mean fluorescent intensity (MFI) of the live cells was
detected, indicative of the quantity of beads internalised.
Confocal laser scanning microscopy
Cells destined for confocal microscopy were plated at 5000
cells/well on 8-mm #1.5 glass coverslips (Menzel Gläser,
Germany) within a 48-well plate. Fluoresbrite® YG carb-
oxylate microspheres of 1-μm diameter (1:10,000 dilution)
were added to cells for 24 h at 37 °C, 5 % CO2 and at com-
pletion washed twice in PBS to remove un-phagocytosed
beads. Cells were fixed in 4 % PFA and immunostained for
platelet-derived growth factor receptor beta (PDGFRβ) as
per immunocytochemistry, with the exception of diluting
primary and secondary antibodies in donkey immunobuffer
(1 % donkey serum, 0.2 % Triton X-100 and 0.04 % thimer-
osal in PBS). Coverslips were mounted onto glass slides
using fluorescent mounting medium (DAKO, Denmark).
Confocal images were acquired using an oil immersion lens
(×63 magnification, 1.4NA) in a Z-series with a gap of
0.8 μm using a Zeiss LSM 710 inverted confocal micro-
scope (Biomedical Imaging Research Unit, University of
Auckland) with ZEN 2010 software (Carl Zeiss, Germany).
EdU proliferation assay
5-Ethynyl-2′-deoxyuridine (EdU; 10 μM) was added to
pericyte cultures 24 h prior to completion of experiment.
Cells were fixed in 4 % PFA for 15 min and EdU visualised
as per manufacturer’s instructions (Life Technologies, CA,
USA). Cell nuclei were counterstained with Hoechst
33258 as per immunocytochemistry.
Alamar Blue® viability assay
To determine cell viability, Alamar Blue® (1:10 final dilu-
tion in culture medium; Life Technologies, CA, USA) was
added to cells in a 96-well plate for 2 h at 37 °C, 5 % CO2.
Fluorescence (Ex 544/ Em 590) was read on a FLUOStar
Optima plate reader (BMG Labtech, Germany). Back-
ground fluorescence of wells with media but no cells was
subtracted from all values, and fluorescence intensity
values were normalised to cell number using imaging of
Hoechst positive cells. Fluorescence intensity values were
then normalised to vehicle control.
LDH cytotoxicity assay
To determine cellular toxicity, extracellular lactate de-
hydrogenase (LDH) was detected as per manufacturer’s
instructions (Roche, Switzerland). Briefly, a positive con-
trol was first prepared by lysing cells through addition of
DMEM/F12 media containing 1 % Triton X-100. The
culture media from all samples was then transferred to a
new plate and centrifuged at 160×g for 10 min at room
temperature. To a new 96-well plate, 50 μL of centri-
fuged media was transferred and 50 μL of LDH reaction
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mixture was added. The plate was incubated at room
temperature for 30 min and absorbance measured at
540 nm on a FLUOStar Optima plate reader. Absorb-
ance of culture media containing no cells was subtracted
from all values and the absorbance normalised to that of
the positive control (100 % cytotoxicity).
Quantitative real-time reverse transcriptase PCR
Cells destined for quantitative real-time reverse tran-
scriptase PCR (qRT-PCR) were plated at 100,000 cells/
well in a six-well plate. At completion of the experi-
ment, cells were washed in PBS and RNA extraction,
and purification was performed using the RNeasy® mini
kit (Qiagen, Netherlands) as per manufacturer’s instruc-
tions from duplicate wells. RNA was treated with
DNase I (1 μg DNase I/1 μg RNA) using the RQ1
RNase-free DNAse kit (Promega, WI, USA) and cDNA
made using the Superscript® III First-Strand Synthesis
kit (Life Technologies, CA, USA). Quantitative real-
time PCR was performed using Platinum® SYBR® Green
qPCR SuperMix-UDG with Rox (Life Technologies,
CA, USA) on a 7900HT Fast Real-Time PCR system
(Applied Biosystems, Life Technologies, CA, USA).
Standard curves were run for all primers, and efficien-
cies were all 100 ± 10 % (Additional file 2: Table S2).
Relative gene expression analysis was performed using
the 2−ΔΔCt method to the housekeeping gene GAPDH.
Microarray
Microarray analysis of TGFβ1-treated pericytes was con-
ducted on technical triplicates of a single patient donor.
Cells destined for microarray were treated for 72 h with
vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or
10 ng/mL TGFβ1. Cells were washed in PBS and lysed in
1 mL of TRIzol reagent (Life Technologies, CA, USA).
To this, 200 μL of chloroform was added, and samples
were vigorously shaken and centrifuged at 12,000×g for
15 min at 4 °C. The upper aqueous phase was trans-
ferred to a new tube and an equal volume of 70 % etha-
nol added. RNA purification was performed using the
RNeasy® mini kit as per qRT-PCR experiments. RNA
quality was analysed using a 2100 Bioanalyzer (Agilent
Technologies, CA, USA) with all samples having a RIN
value of 10. RNA was labelled and hybridised to Affyme-
trix Genechip® Primeview™ Human Gene Expression
Arrays (Santa Clara, CA, USA) according to manufac-
turer’s instructions. Microarray was performed and ana-
lysed by New Zealand Genomics Limited (NZGL).
Candidate microarray hits for qRT-PCR and CBA valid-
ation were selected based on the magnitude of change
and prior evidence for involvement in neuro-immune re-
sponses but do not include all modified inflammatory
genes.
Statistical analysis
Unless otherwise stated, all experiments were performed
at least three independent times on tissue from three
different donors. Statistical analysis was carried out
using an unpaired Student’s t test, one-way analysis of
variance (ANOVA) with Dunnett’s multiple comparison
test to compare treatments versus vehicle control,
ANOVA with Newman-Keuls multiple comparison test
to compare all conditions, or a two-way ANOVA to
compare the effect of both time and cytokine stimula-
tion (Graphpad Prism 5.02). For statistical analysis of
qRT-PCR data, ΔCt values were used. Statistical analysis
of microarray data was performed as described previ-
ously [37].
Results
TGFβ1 modifies inflammatory gene expression in human
brain pericytes
The role of TGFβ1 in modifying pericyte phenotype and
associated functional responses including scarring, pro-
liferation and differentiation has been previously studied
[43, 44]. However, its effect on pericyte-mediated
immune responses has not been well characterised. Pre-
vious work from our lab has identified a potential anti-
inflammatory role for TGFβ1 in pericytes through
prevention of IFNγ-induced HLA-DR expression [27]. In
order to further understand the inflammatory phenotype
adopted by TGFβ1-stimulated brain pericytes, microarray
analysis was undertaken. As expected, several inflammatory
genes showed attenuated expression, including interleukin
8 (IL8), p = 8.06−4; CX3CL1, p = 3.09−6; monocyte chemo-
attractant protein 1 (MCP1), p = 2.98−6; and vascular cell
adhesion molecule 1 (VCAM1), p = 5.57−7 (Fig. 1a). Sur-
prisingly, however, a number of inflammatory-related genes
were also found to be induced by TGFβ1 treatment, includ-
ing nicotinamide adenine dinucleotide phosphate-oxidase 4
(NOX4), p = 1.12−6; cyclooxygenase 2 (COX2), p = 1.35−6;
matrix metalloproteinase 2 (MMP2), p = 1.09−4; and inter-
leukin 6 (IL6), p = 2.03−4 (Fig. 1a). These changes were con-
firmed by qRT-PCR with TGFβ1-induced up-regulation of
NOX4 (p < 0.001; Fig. 1b), COX2 (p < 0.001; Fig. 1c),MMP2
(p < 0.05; Fig. 1d) and IL6 (p < 0.05; Fig. 1e) and attenuation
of IL8 (p < 0.05; Fig. 1f), CX3CL1 (p < 0.01; Fig. 1g), MCP1
(p < 0.001; Fig. 1h) and VCAM1 (p < 0.001; Fig. 1i) at 72 h.
Furthermore, several changes were apparent as early as
24 h after TGFβ1 treatment (NOX4, p < 0.001, Fig. 1b;
COX2, p < 0.001, Fig. 1c; IL8, p < 0.01, Fig. 1f; MCP1, p <
0.001, Fig. 1h and VCAM1, p < 0.001, Fig. 1i).
TGFβ1 modifies inflammatory protein secretion in human
brain pericytes
Having identified a role for TGFβ1 in modifying pericyte
inflammatory gene expression, we sought to ascertain
whether this translated to a functional change in protein
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levels. Several of the genes affected by TGFβ1 are secreted
cytokines, chemokines or cleavable/secreted adhesion
molecules. We therefore determined the concentration of
these proteins in conditioned media from TGFβ1-treated
pericytes. All tested inflammatory mediators were found
to be secreted basally by pericytes and, consistent with
microarray and qRT-PCR results, a 72-h treatment with
TGFβ1 attenuated this secretion of soluble VCAM-1
(sVCAM-1; p < 0.001; Fig. 2a), CX3CL1 (p < 0.001; Fig. 2b)
and MCP-1 (p < 0.001; Fig. 2c). Interestingly, the expres-
sion of IL-8 was found to be unchanged (p > 0.05, Fig. 2d).
Furthermore, IL-6 secretion was significantly enhanced by
TGFβ1 treatment (p < 0.001; Fig. 2e). Secretions of
sVCAM-1 (p < 0.001; Fig. 2a) and CX3CL1 (p < 0.05;
Fig. 2b) were significantly decreased after a 24-h treatment
with TGFβ1, whilst MCP-1 attenuation (p < 0.001; Fig. 2c)
and IL-6 induction (p < 0.001; Fig. 2e) was apparent at
48 h.
Synergistic and preventative effects of TGFβ1 on IL-1β-
induced inflammatory protein secretion
As TGFβ1 appears to be a critical modifier of the peri-
cyte immune phenotype, we sought to investigate its
ability to attenuate or synergize with IL-1β, another pro-
Fig. 1 TGFβ1 modifies inflammatory gene expression in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM
citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 72 h. RNA was extracted and expression of inflammation-related genes determined by
microarray (a). Changes in gene expression (NOX4 (b), COX2 (c), MMP2 (d), IL6 (e), IL8 (f), CX3CL1 (g), MCP1 (h) and VCAM1 (i)) were confirmed by
qRT-PCR from three independent experiments with 0–72 h treatments with 10 ng/mL TGFβ1. *p < 0.05, **p < 0.01, ***p < 0.001 versus 0 h time
point (ANOVA)
Rustenhoven et al. Journal of Neuroinflammation  (2016) 13:37 Page 5 of 15
inflammatory cytokine. IL-1β alone significantly enhanced
the basal secretion of sVCAM-1 (p < 0.001; Fig. 3a),
CX3CL1 (p < 0.001; Fig. 3b), MCP-1 (p < 0.001; Fig. 3c),
IL-8 (p < 0.001; Fig. 3d) and IL-6 (p < 0.001; Fig. 3e).
TGFβ1 was found to significantly reduce IL-1β-induced
sVCAM-1 (p < 0.001; Fig. 3a), CX3CL1 (p < 0.001; Fig. 3b)
and MCP-1 (p < 0.001; Fig. 3c) secretions; however, it had
no effect on IL-8 expression (p > 0.05, Fig. 3d). Further-
more, co-stimulation of pericytes with IL-1β and TGFβ1
showed a synergistic release of IL-6, well above that seen
with IL-1β treatment alone (p < 0.001, Fig. 3e).
TGFβ1 signals through SMAD2/3 transcription factors but
does not affect NF-kB translocation
Inflammatory protein expression is largely controlled by
transcription factor-mediated gene transcription. In order
to further understand how TGFβ1 modifies the pericyte
immune response, we investigated the ability of this cyto-
kine to modify the localisation of two transcription factors,
SMAD2/3 and nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB). Whilst SMAD2/3 showed a
low level of basal nuclear localisation, TGFβ1 treatment
significantly enhanced this at 2 h (p < 0.001; Fig. 4a, b),
and remained slightly elevated (albeit not significantly) for
up to 48 h (p > 0.05; Fig. 4a, b). IL-1β was found to have
no effect on SMAD2/3 nuclear localisation at 2, 24 or
48 h (p > 0.05) alone and did not alter TGFβ1-induced nu-
clear localisation at any time point (p > 0.05; Fig. 4a, b).
IL-1β significantly enhanced nuclear translocation of NF-
kB at 2 h (p < 0.001) but not 24 h (p > 0.05) or 48 h (p >
0.05), whilst TGFβ1 has no effect at any time point (p >
0.05; Fig. 4a, c). Furthermore, TGFβ1 did not modify IL-
Fig. 2 TGFβ1 modifies inflammatory protein secretion in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM
citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h, and conditioned media was collected. Concentration of secreted proteins
(sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8 (d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment
(N = 4 wells) from three independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control at each time point
(two-way ANOVA)
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1β-induced NF-kB translocation at 2 h (p > 0.05), 24 h
(p > 0.05) or 48 h (p > 0.05; Fig. 4a, c).
TGFβ1 attenuates phagocytosis by pericytes
Phagocytosis is a critical function of specific immune cells
and is necessary to clear pathogenic substances from the
brain [47]. Inflammatory cytokines, including TGFβ1, have
previously been shown to modify the phagocytic ability of
parenchymal brain cells, particularly microglia and astro-
cytes. Given the ability of TGFβ1 to modify pericyte in-
flammatory responses, we queried whether it could
influence phagocytosis by these cells. TGFβ1 significantly
attenuated pericyte phagocytosis of fluorescent latex beads
at 1 ng/mL (p < 0.01) or 10 ng/mL (p < 0.001) as deter-
mined by an automated imaging-based assay (Fig. 5a, b).
To confirm that beads were internalised and not simply
bound to the cell membrane confocal microscopy was
performed (Fig. 5c). A flow cytometry based assay was also
employed to measure phagocytosis which again revealed a
significant reduction in phagocytic ability by pericytes fol-
lowing a 10 ng/mL TGFβ1 treatment (p < 0.05, Fig. 5d, e)
whilst lower concentrations trended towards a reduction.
TGFβ1 reduces gene expression of scavenger receptors
Scavenger receptors have a key role in recognising and co-
ordinating the uptake of a wide range of macromolecules,
including fluorescent beads and disease related proteins
such as amyloid beta [48, 49]. As TGFβ1 was found to in-
hibit the phagocytic ability of pericytes, we investigated its
ability to modify the expression of receptors involved in
scavenging macromolecules. A 24-h treatment with TGFβ1
was found to significantly attenuate pericyte expression, as
Fig. 3 Synergistic and preventative effects of TGFβ1 on IL-1β-induced inflammatory protein secretion. Primary human brain pericytes were treated
with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h followed by a further 24 h in the presence of 10 ng/mL IL-1β or
vehicle (0.1 % BSA in PBS). Conditioned media was collected and the concentration of secreted proteins (sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8
(d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment (N = 4 wells) from three independent
experiments is shown. ***p < 0.001 (ANOVA)
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determined by qRT-PCR, of the receptors CD36 (p < 0.001,
Fig. 6a), CD68 (p < 0.05, Fig. 6b) and CD47 (p < 0.05,
Fig. 6c), highlighting a possible mechanism behind TGFβ1-
reduced phagocytic ability.
TGFβ1 reduces pericyte proliferation but does not affect
their viability
Functional responses of cells, including phagocytosis,
can be influenced by general changes in cell viability. In
Fig. 4 TGFβ1 signals through SMAD2/3 transcription factors but does not affect NF-kB translocation. Primary human brain pericytes were treated
for 0–48 h with combinations of vehicle (1 mM citric acid, pH 3 with 0.1 % BSA), 10 ng/mL TGFβ1 and 10 ng/mL IL-1β. Cells were fixed and
immunostained for NF-kB p65 and SMAD2/3. Representative images at 2 h are shown (a). The intensity of nuclear NF-kB (b) and
nuclear SMAD2/3 (c) was determined by automated image analysis from four independent experiments. ***p < 0.001 versus vehicle
control at each time point (two-way ANOVA). Scale bar = 50 μm
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order to exclude the possibility that TGFβ1 modifies
phagocytosis through compromising pericyte viability,
we undertook a range of assays with respect to examin-
ing cell health. TGFβ1 was unable to stimulate pericyte
apoptosis, as determined by antibody labelling and im-
aging of the early apoptotic marker cleaved caspase 3
(CC3) at any time point (p > 0.05; Fig. 7a, b). Due to the
low level of basal pericyte apoptosis, validation of the
CC3 antibody was determined by okadaic acid-induced
apoptosis (Fig. 7a, b). TGFβ1 treatment did result in a
significant reduction of EdU positive cells, indicative of re-
duced cell proliferation, at 24, 48 and 72 h (p < 0.001;
Fig. 5 TGFβ1 attenuates phagocytosis by pericytes. Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 %
BSA, followed by a further 24 h in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Cells were fixed and nuclei
counterstained with DRAQ5. Representative images for vehicle and 10 ng/mL TGFβ1 treatments are shown (a). The percentage of phagocytic
pericytes was determined by automated image analysis from five independent experiments (b). Confocal microscopy of pericytes plated on glass
coverslips, incubated for 24 h with a 1:10,000 dilution of fluorescent beads and immunostained with PDGFRβ confirmed internalisation of beads
(c). Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 % BSA. For an additional two hours cells were
incubated in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Phagocytosis was determined by flow cytometry. One
representative plot is shown (d) and the mean fluorescent intensity (MFI) of five independent experiments was determined (e). *p < 0.05, **p <
0.01, ***p < 0.001 versus vehicle control (ANOVA). Scale bar = 50 μm
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Fig. 7c, d). However, these proliferative changes resulted
in only small, albeit significant (48 h, p < 0.01; 72 h, p <
0.001), reductions in cell number (Fig. 7e). Cellular cyto-
toxicity, as determined by LDH release, revealed no
change with TGFβ1 treatment at any time point (p > 0.05;
Fig. 7f) whilst an Alamar Blue® viability assay showed an
increase at 24, 48 and 72 h (p < 0.001; Fig. 7g).
Discussion
TGFβ1 is a pleotropic cytokine that has been widely stud-
ied with respect to CNS inflammatory responses. Due to a
ubiquitous anti-inflammatory microglial phenotype in re-
sponse to TGFβ1 stimulation, several studies have sug-
gested utilisation of TGFβ1 in limiting brain inflammation
[10, 26–28]. However, microglia are not the only immuno-
logically active parenchymal brain cell, and therefore, in-
vestigating the effect of TGFβ1 treatment on other cell
types is warranted. Several groups, including our own,
have shown that human brain pericytes can produce in-
flammatory responses in vitro and that these responses do
not necessarily mimic microglial responses [27, 50].
To investigate transcriptome-wide changes in inflamma-
tory mediators, microarray analysis of human brain peri-
cytes treated with TGFβ1 was first performed. Whilst
several inflammatory mediators displayed an attenuated ex-
pression as expected, a number of inflammatory genes were
also found to be up-regulated following TGFβ1 stimulation.
Eight genes were chosen for qRT-PCR validation consisting
of four up-regulated genes (IL6, MMP2, NOX4 and COX2)
and four down-regulated genes (VCAM1, IL8, MCP1 and
CX3CL1). As observed previously, qRT-PCR data corre-
lated strongly with microarray analysis, with all genes ex-
amined showing consistent trends [37]. In order to confirm
mRNA changes at the protein level, a cytometric bead array
was employed to measure soluble and secreted concentra-
tions of the aforementioned cytokines, chemokines and ad-
hesion molecules. With the exception of IL-8, TGFβ1 was
found to modify inflammatory mediator secretions in a
manner consistent with microarray and qRT-PCR data.
Furthermore, when co-stimulated with TGFβ1 and the pro-
inflammatory cytokine IL-1β, IL-6 expression was synergis-
tically induced whilst MCP-1, CX3CL1, VCAM-1 and
MCP-1 all demonstrated reduced secretions.
Like TGFβ1, the function of IL-6 in the brain has been
widely studied but is not well defined. In certain instances,
IL-6 appears to act as a pro-inflammatory cytokine further
enhancing CNS immune responses [51, 52]. Paradoxically,
IL-6 also appears to have anti-inflammatory functions and
can aid neuronal survival in the presence of inflammation
[51, 53]. Similarly, COX-2 induction has been widely de-
bated with regards to its inflammatory phenotype. Whilst
initially perceived to have a solely pro-inflammatory func-
tion, many of the COX-2-derived prostaglandins can have
anti-inflammatory effects in a cell- and context-dependent
manner [54–56].
MMP-2 is a matrix metalloproteinase involved in the
breakdown of extracellular matrix (ECM) proteins, in-
cluding type IV collagen, a major constituent of the
basement membrane [57]. MMP-2 expression in the vas-
culature promotes BBB breakdown through reduced
basement membrane expression and endothelial tight
junction deregulation, subsequently enhancing leukocyte
infiltration [58–60]. MMP-2 also facilitates cancer cell
invasion in glioblastoma multiforme, a brain tumour in
which TGFβ1 is highly expressed [61–63]. Furthermore,
MMP-2 can cleave non ECM substrates, including latent
TGFβ1 which can promote an increased release of its ac-
tive form, potentially creating a positive feedback loop
[64]. TGFβ1-enhanced MMP-2 expression has been re-
cently observed in brain pericytes, corroborating our
data [65]. NOX4 is a member of the NADPH oxidase
family and contributes to cellular superoxide production.
NOX family members are highly expressed in profes-
sional phagocytic cells and reactive oxidative species
(ROS) are crucial in the killing of micro-organisms [66].
However, NOX-derived ROS have also been implicated
in arteriosclerosis, disturbance of vascular tone, disrup-
tion of the BBB and endothelial cell apoptosis through
oxidative stress [67–69]. NOX4 induction is a character-
istic feature in the vasculature, showing expression in
Fig. 6 TGFβ1 reduces gene expression of scavenger receptors. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3
with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h. RNA was extracted and expression of CD36 (a), CD68 (b) and CD47 (c) and determined by qRT-PCR
from three independent experiments. *p < 0.05, ***p < 0.001 versus vehicle control (Student’s t test)
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the endothelium [70, 71], vascular smooth muscle cells
[72, 73] and more recently human brain pericytes [74].
TGFβ1-mediated MMP-2 and NOX4 induction may
therefore have a significant impact in the disruption of
CNS vasculature following injury.
Cytometric bead array was also performed to examine
soluble VCAM-1, MCP-1, IL-8 and CX3CL1 secretions.
Whilst VCAM-1, MCP-1, and CX3CL1 all showed attenu-
ated secretions with TGFβ1, the level of IL-8 was not sig-
nificantly altered. A similar response has been observed
previously in our lab whereby changes in IL-8 mRNA did
not correlate with IL-8 secretions [42]. The reasons for
this discrepancy are currently unclear.
VCAM-1 is an adhesion molecule expressed by cells
of the vasculature, including endothelial cells and peri-
cytes [40, 75]. Unlike the related adhesion molecule
intracellular adhesion molecule 1 (ICAM-1), VCAM-1
was found to be expressed under basal conditions by
human brain pericytes [42]. VCAM-1 aids the adhesion
and subsequent transmigration of leukocytes across brain
Fig. 7 TGFβ1 decreases pericyte proliferation but does not affect their viability. Primary human brain pericytes were treated with vehicle (1 mM
citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cells were fixed and immunostained for cleaved caspase 3 (CC3). Nuclei were
counterstained with Hoechst. Cells treated for 24 h with 50 nM okadaic acid (OA) were used as a positive control. Representative images from the
24 h time point are shown (a). The percentage of CC3 positive cells was determined by automated image analysis from three independent
experiments (b). Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h.
For the final 24 h, cells were incubated with 10 μM EdU. Cells were fixed, EdU visualised and nuclei counterstained with Hoechst. Representative
images from the 72-h time point are shown (c). The percentage of EdU positive cells (d), and the number of cells/field of view was determined
by automated image analysis from three independent experiments (e). Primary human brain pericytes were treated with vehicle (1 mM citric acid,
pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cytotoxicity was determined from three independent experiments by an LDH release assay
using cells lysed with DMEM/F12 containing 1 % Triton-X 100 as a positive control (f). Viability was determined from three independent experiments
by a two hour treatment with Alamar Blue (g). *p< 0.05, **p< 0.01, ***p< 0.001 versus vehicle control for each time point (two-way ANOVA).
Scale bar= 50 μm
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vasculature [76]. This interaction occurs via binding of
very late antigen-4 (VLA-4), an integrin which undergoes
conformational changes to allow VCAM-1 mediated ad-
hesion after chemotactic activation [75–78]. Whilst typic-
ally implicated in endothelial-immune cell interactions,
pericytes can also control immune cell adhesion and mi-
gration across the BBB [40, 79]. MCP-1 is a monocyte
chemokine that attracts peripheral immune cells through
a concentration-dependent gradient. Elevated MCP-1 ex-
pression is observed in the brain following an insult and
chemoattracts parenchymal microglia as well as peripheral
circulating leukocytes to the injured site, thereby contrib-
uting to a pro-inflammatory CNS phenotype [80–82].
Attenuated VCAM-1 and MCP-1 expression could there-
fore represent an anti-inflammatory function of TGFβ1
through limiting peripheral immune cell infiltration.
Fractalkine (CX3CL1) is a unique protein which func-
tions as an adhesion molecule when membrane-bound,
or a leukocyte chemokine in its soluble form [83–86].
Like MCP-1 and VCAM-1, attenuated expression of this
mediator could thereby limit peripheral immune cell
CNS entry. However, the effects of CX3CL1 are exerted
specifically through the fractalkine receptor (CX3CR1)
and whilst circulating leukocytes express this receptor
[83, 87], in the brain, CX3CR1 expression is limited pre-
dominantly to microglia [88]. CX3CL1-CX3CR1 interac-
tions in the CNS promote a strong anti-inflammatory
microglial phenotype, whilst CX3CR1 knockout mice
showed microglial-mediated neurotoxicity [88–90]. Frac-
talkine signalling therefore appears to be vital in control-
ling microglial inflammatory responses. CX3CL1 is
believed to be expressed predominantly by neurons in
the CNS [90], and to our knowledge, this is the first evi-
dence of fractalkine secretion by brain pericytes and this
highlights a possible role for these cells in modulating
microglial inflammation. TGFβ1-attenuated CX3CL1 ex-
pression in pericytes may therefore deregulate microglial-
mediated immune responses.
Modifications of cellular inflammatory responses are
largely controlled through transcription factor-mediated
gene transcription. Consistent with previous literature,
TGFβ1 produced a pronounced induction of nuclear
SMAD2/3 [91, 92]. However, it failed to induce nuclear
translocation of NF-kB alone or modify the IL-1β-induced
localisation of NF-kB. Previous studies, albeit in different
cell types, report both TGFβ1-mediated NF-kB transloca-
tion or lack thereof [93, 94]. This discrepancy highlights the
cell-specific effects of TGFβ1. Indeed, cell type-dependent
responses with TGFβ1 have been observed previously in
our lab with respect to astrocyte and microglial inflamma-
tory responses [27]. Surprisingly, although TGFβ1-induced
SMAD2/3 nuclear localisation was largely absent after 24 h,
the induction of several inflammatory markers approached
their peak 72 h after TGFβ1 treatment. It is therefore
unlikely that SMAD2/3-modified gene transcription was
directly involved in stimulating certain TGFβ1-induced
inflammatory changes. Instead, it is possible that the early
induction of select markers, particularly NOX4, could influ-
ence the expression of other inflammatory proteins. Indeed,
pericyte-derived NOX4 has been previously implicated in
BBB breakdown through enhanced neuroinflammatory re-
sponses, including MMP-9 induction [95]. Whilst it is cur-
rently unclear precisely how TGFβ1 modifies pericyte
inflammatory responses, it appears that it is not through
the prototypical inflammatory transcription factor NF-kB.
Further studies examining a role for SMAD transcription
factors in pericyte immune responses are therefore
required
Aside from their role in expressing inflammatory media-
tors, brain pericytes also possess phagocytic ability with re-
spect to latex beads and other particulate matter [41, 96].
Using confocal microscopy, we confirmed that our pericyte
cultures were capable of phagocytosis in vitro and this func-
tion was able to be quantitatively determined by micros-
copy- and flow cytometry-based assays. TGFβ1 was found
to significantly reduce the phagocytic uptake of latex beads
in a concentration-dependent fashion. Interestingly, en-
hanced expression of TGFβ1 in the brain significantly ele-
vates fibrillar amyloid beta deposition, exclusively in the
vasculature [29, 97]. Our results suggest that TGFβ1-atten-
uated phagocytic function could contribute to the increased
vasculature-associated amyloid. Due to their phagocytic
ability and anatomical location, it is possible that pericytes
have a key role in clearing pathogenic substances from the
brain parenchyma. Indeed, pericytes have recently been
shown to internalise amyloid beta, whilst their loss acceler-
ates cerebral amyloid angiopathy [98]. Despite showing
phagocytic capability, it is important to note that their rate
of uptake was notably lower than that of microglia, the
brains resident macrophage [99].
Whilst it is currently unclear precisely how TGFβ1 re-
duced pericyte phagocytic function, it was found to de-
crease the expression of the scavenger receptors CD36,
CD47 and CD68. These receptors recognise a range of
macromolecules, including latex beads and amyloid beta,
and stimulate their internalisation [100, 101]. Inhibition
of CD36 and CD47 can prevent phagocytic function [48,
102, 103] whilst TGFβ1 has previously been shown to at-
tenuate CD36 expression in macrophages [104, 105].
As well as specific receptor involvement, alterations in
phagocytosis may be achieved simply by modifying cell
viability. Due to the range of inflammatory mediators in-
duced by TGFβ1, this was certainly a possibility. Indeed,
TGFβ1-induced NOX4 has been shown to precipitate
endothelial cell apoptosis through oxidative stress [106].
In order to exclude a generalised loss of pericyte viability
in this phagocytic response, we examined the effect of
TGFβ1 on pericyte health. Whilst a decrease in cell
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number was observed with TGFβ1 treatment, this was
explained by a reduction in pericyte proliferation and
not apoptotic or necrotic death or alterations in viability.
Aside from pericytes, several other cells of the neuro-
vasculature unit, including microglia [25], astrocytes [11]
and endothelial cells [106], contain TGFβR’s and may
therefore contribute to TGFβ1-induced immune re-
sponses. Whilst TGFβ1 has been previously studied with
respect to in vivo neurovasculature function, the ability
of numerous cell types to respond to this growth factor
compromises the ability to study cell type-specific func-
tions, particularly secreted cytokines, chemokines and
ROS production. Indeed in differing in vivo models,
TGFβ1 has been shown to exacerbate BBB permeability
through MMP-9 induction [107] as well as preventing
BBB breakdown through MMP9 suppression [108].
Whilst understanding the role of TGFβ1 in each cell type
is vital in understanding whole-organism changes, it
should be emphasised that isolated pericyte cultures lack
the paracrine signalling with other parenchymal brain
cells present in vivo, and the functional outcomes of
TGFβ1 expression in the neurovasculature could differ
as a result.
Conclusions
TGFβ1 attenuated the expression of key chemokines and
adhesion molecules involved in CNS leukocyte traffick-
ing and control of microglial function, as well as redu-
cing their phagocytic ability. However, it also enhanced
the expression of classical pro-inflammatory cytokines
and enzymes which can disrupt BBB function. Together,
these data suggest that TGFβ1 induction following brain
injury stimulates a unique phenotype in brain pericytes
which is neither specifically pro- nor anti-inflammatory.
The functional in vivo outcome of TGFβ1-stimulation
on brain pericytes is therefore difficult to predict. How-
ever, the reduction in pericyte proliferation, combined
with elevated IL-6, MMP-2 and NOX4 expression, as
well as attenuated phagocytic functioning, suggests a
detrimental action of TGFβ1 on the neurovasculature.
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